Form 4: Reshape Lifesciences CFO Thomas Stankovich Reports Stock Sales to Cover Taxes

Thomas Stankovich, CFO of ReShape Lifesciences Inc., reports the sale of company stock to cover taxes related to the vesting of restricted stock units.

Summary

• Thomas Stankovich, the Chief Financial Officer of ReShape Lifesciences Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• The reported transactions involve the sale of common stock to cover taxes associated with the vesting of restricted stock units previously awarded to Mr. Stankovich.
• The sales occurred on November 30, 2023 (39 shares at $0.23), December 31, 2023 (42 shares at $0.25), February 29, 2024 (43 shares at $0.17), and May 31, 2024 (48 shares at $0.25).
• Following these transactions, Mr. Stankovich directly owns 22,777 shares of ReShape Lifesciences Inc. common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock sales for tax purposes, indicating a neutral sentiment.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the buying and selling activities of company executives and directors. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The stock sales by the CFO could have a minor impact on shareholder sentiment, but are unlikely to significantly affect the company's operations or financial condition.

Key Dates

Keywords

Form 4, Reshape Lifesciences, RSLS, Thomas Stankovich, CFO, stock sale, beneficial ownership, restricted stock units, tax obligations